Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
9.24
+0.99 (12.00%)
Aug 12, 2025, 4:00 PM - Market closed
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Fennec Pharmaceuticals stock have an average target of 13, which predicts a 40.69% increase from the current stock price of 9.24.
Price Target: $13 (+40.69%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 20, 2025.
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +40.69% | May 20, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $13 | Strong Buy | Maintains | $12 → $13 | +40.69% | May 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +40.69% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +40.69% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $13 | Strong Buy | Maintains | $15 → $13 | +40.69% | Aug 22, 2024 |
Financial Forecast
Revenue This Year
47.94M
from 47.54M
Increased by 0.85%
Revenue Next Year
74.38M
from 47.94M
Increased by 55.16%
EPS This Year
0.17
from -0.02
EPS Next Year
0.84
from 0.17
Increased by 391.67%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.1M | 92.1M | 110.5M | ||
| Avg | 47.9M | 74.4M | 94.9M | ||
| Low | 41.4M | 65.2M | 80.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.9% | 92.2% | 48.6% | ||
| Avg | 0.8% | 55.2% | 27.6% | ||
| Low | -13.0% | 36.0% | 8.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.44 | 1.10 | 1.93 | ||
| Avg | 0.17 | 0.84 | 1.52 | ||
| Low | -0.14 | 0.65 | 1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 543.4% | 129.3% | ||
| Avg | - | 391.7% | 80.0% | ||
| Low | - | 277.5% | 18.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.